RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Hansa Biopharma Stock

Hansa Biopharma Employees 2024

Hansa Biopharma Employees

78

Ticker

HNSA.ST

ISIN

SE0002148817

WKN

A0M65T

In 2024, Hansa Biopharma employed 78 people, a 0% change from the 78 number of employees in the previous year.

Hansa Biopharma Aktienanalyse

What does Hansa Biopharma do?

Hansa Biopharma AB is a Swedish biotechnology company specializing in the development of therapy options for rare immune and inflammatory diseases. The company was founded in Lund in 1986 and now has branches in the USA and Japan. The company's business model and divisions include clinical development, corporate development, and production. The clinical development division focuses on conducting clinical studies to demonstrate the effectiveness and safety of new drugs. The corporate development division handles collaboration with regulatory authorities, investors, and other partners. The production division encompasses the manufacturing of products developed by Hansa Biopharma AB. The company's products include Idefirix, an antibody-based drug candidate for the treatment of severe hemolysis due to alloimmune blood group antibodies, and an immunoglobulin production technology platform for the development of antibody therapies for various diseases. Hansa Biopharma AB's roots date back to 1986 when it was established as a spin-off from Lund University. Initially, the company focused on the development and production of diagnostics and reagents for immunology and clinical chemistry. In recent years, it shifted its focus to developing innovative therapies for rare immune and inflammatory diseases. In 2010, the company made a breakthrough with the discovery of the 174H target, which led to the development of Idefirix. Idefirix has since successfully completed phase III clinical trials and may soon be approved for the treatment of severe hemolysis. In conclusion, Hansa Biopharma AB is a leading biotechnology company with a strong vision and clear strategy for developing innovative therapies for rare immune and inflammatory diseases. The company specializes in antibody therapies and is currently focused on the development of Idefirix and the expansion of its immunoglobulin production technology platform. With a strong research pipeline and experienced management team, Hansa Biopharma AB is well-positioned to make significant progress in the coming years and develop innovative therapies for patients with rare diseases. Hansa Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Hansa Biopharma's Employee Base

Hansa Biopharma's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Hansa Biopharma's operational capacity and future potential.

Year-to-Year Comparison

Assessing Hansa Biopharma's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Hansa Biopharma's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Hansa Biopharma’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Hansa Biopharma stock

How many employees does Hansa Biopharma have this year?

Hansa Biopharma has 78 undefined employees this year.

How many employees did Hansa Biopharma have compared to the previous year?

Compared to the previous year, Hansa Biopharma had 0% more employees.

What impact did the number of employees have on the company Hansa Biopharma?

The number of employees has a direct impact on the efficiency and productivity of Hansa Biopharma. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Hansa Biopharma?

The number of employees can also have an impact on investors of Hansa Biopharma, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Hansa Biopharma affect the company?

An increase in equity of Hansa Biopharma can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Hansa Biopharma's equity affect the company?

A reduction in equity of Hansa Biopharma can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Hansa Biopharma?

Some factors that can influence the equity of Hansa Biopharma include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Hansa Biopharma so important for investors?

The equity of Hansa Biopharma is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Hansa Biopharma influence the company?

The number of employees at Hansa Biopharma can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Hansa Biopharma evolved in recent years?

In recent years, the number of employees at Hansa Biopharma has changed by 0.

How many employees does Hansa Biopharma currently have?

Hansa Biopharma currently has 78 undefined employees.

Why is the number of employees important for investors of Hansa Biopharma?

The number of employees is important for investors of Hansa Biopharma as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Hansa Biopharma take to change the number of employees?

To change the number of employees, Hansa Biopharma can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Hansa Biopharma pay?

Over the past 12 months, Hansa Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hansa Biopharma is expected to pay a dividend of 0 SEK.

What is the dividend yield of Hansa Biopharma?

The current dividend yield of Hansa Biopharma is .

When does Hansa Biopharma pay dividends?

Hansa Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hansa Biopharma?

Hansa Biopharma paid dividends every year for the past 0 years.

What is the dividend of Hansa Biopharma?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hansa Biopharma located?

Hansa Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hansa Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hansa Biopharma from 9/20/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 9/20/2024.

When did Hansa Biopharma pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of Hansa Biopharma in the year 2023?

In the year 2023, Hansa Biopharma distributed 0 SEK as dividends.

In which currency does Hansa Biopharma pay out the dividend?

The dividends of Hansa Biopharma are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Hansa Biopharma

Our stock analysis for Hansa Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hansa Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.